Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer
Sionna Therapeutics (Nasdaq: SION), a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis (CF), has appointed Caroline Stark Beer, MBA as Chief Business Officer. Beer brings over 20 years of life science industry experience, most recently serving as CBO at Jnana Therapeutics until its acquisition by Otsuka Pharmaceutical.
Beer's previous experience includes a decade at Alnylam Pharmaceuticals where she served as VP of Business Development, leading significant partnerships including a 5-year collaboration with Regeneron Pharmaceuticals. She holds an MBA from MIT Sloan School of Management and previously worked at Amicus Therapeutics and Bain & Company.
Sionna Therapeutics (Nasdaq: SION), azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di terapie per la fibrosi cistica (CF), ha nominato Caroline Stark Beer, MBA Chief Business Officer. Beer vanta oltre 20 anni di esperienza nell'industria delle scienze della vita, più recentemente come CBO presso Jnana Therapeutics fino all'acquisizione da parte di Otsuka Pharmaceutical.
In precedenza Beer ha trascorso un decennio in Alnylam Pharmaceuticals come VP Business Development, guidando partnership rilevanti tra cui una collaborazione quinquennale con Regeneron Pharmaceuticals. Ha un MBA al MIT Sloan School of Management e ha lavorato anche in Amicus Therapeutics e Bain & Company.
Sionna Therapeutics (Nasdaq: SION), compañía biofarmacéutica en fase clínica centrada en desarrollar tratamientos para la fibrosis quística (FQ), ha nombrado a Caroline Stark Beer, MBA Chief Business Officer. Beer aporta más de 20 años de experiencia en la industria de las ciencias de la vida, y hasta hace poco se desempeñaba como CBO en Jnana Therapeutics, antes de su adquisición por Otsuka Pharmaceutical.
Previamente, Beer pasó una década en Alnylam Pharmaceuticals como VP de Desarrollo de Negocios, liderando alianzas importantes, incluida una colaboración de cinco años con Regeneron Pharmaceuticals. Tiene un MBA del MIT Sloan School of Management y ha trabajado en Amicus Therapeutics y Bain & Company.
Sionna Therapeutics (Nasdaq: SION)은 낭포성 섬유증(CF) 치료제 개발에 주력하는 임상 단계 바이오제약사로, Caroline Stark Beer, MBA를 최고사업책임자(CBO)로 임명했습니다. Beer는 20년 이상의 생명과학 업계 경력을 보유하고 있으며, 최근에는 Otsuka Pharmaceutical에 인수되기 전까지 Jnana Therapeutics의 CBO로 재직했습니다.
이전 경력으로는 Alnylam Pharmaceuticals에서 10년간 비즈니스 개발 부문 부사장(VP)으로 근무하며 Regeneron Pharmaceuticals와의 5년 협력 등 주요 파트너십을 이끌었습니다. MIT 슬론 경영대학원에서 MBA를 취득했으며 Amicus Therapeutics와 Bain & Company에서도 근무한 바 있습니다.
Sionna Therapeutics (Nasdaq: SION), société biopharmaceutique en phase clinique axée sur le développement de traitements contre la mucoviscidose (CF), a nommé Caroline Stark Beer, MBA Chief Business Officer. Beer apporte plus de 20 ans d'expérience dans l'industrie des sciences de la vie, ayant occupé récemment le poste de CBO chez Jnana Therapeutics jusqu'à son acquisition par Otsuka Pharmaceutical.
Auparavant, Beer a passé dix ans chez Alnylam Pharmaceuticals en tant que VP Business Development, pilotant des partenariats importants, dont une collaboration de cinq ans avec Regeneron Pharmaceuticals. Elle est titulaire d'un MBA du MIT Sloan School of Management et a travaillé chez Amicus Therapeutics et Bain & Company.
Sionna Therapeutics (Nasdaq: SION), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf die Entwicklung von Therapien für Mukoviszidose (CF) konzentriert, hat Caroline Stark Beer, MBA zur Chief Business Officer ernannt. Beer bringt über 20 Jahre Erfahrung in der Life-Science-Branche mit und war zuletzt als CBO bei Jnana Therapeutics tätig, bis das Unternehmen von Otsuka Pharmaceutical übernommen wurde.
Zuvor war Beer ein Jahrzehnt bei Alnylam Pharmaceuticals als VP Business Development tätig und leitete bedeutende Partnerschaften, darunter eine fünfjährige Zusammenarbeit mit Regeneron Pharmaceuticals. Sie hat einen MBA vom MIT Sloan School of Management und arbeitete zuvor bei Amicus Therapeutics und Bain & Company.
- Appointment of experienced executive with over 20 years in life science industry
- New CBO has strong track record in forming strategic partnerships and value creation
- Addition strengthens leadership team during clinical development phase
- None.
WALTHAM, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced the appointment of Caroline Stark Beer, MBA, as its Chief Business Officer (CBO).
“We are delighted to welcome Caroline to our executive team at such a pivotal stage for Sionna,” said Mike Cloonan, President and Chief Executive Officer of Sionna. “Caroline’s exceptional experience, leadership, and value creation mindset will enhance our corporate development efforts as we continue to advance toward our goal of delivering innovative and transformative therapies for people living with CF.”
Caroline brings over 20 years of experience in the life science industry to her role with Sionna. She was most recently CBO at Jnana Therapeutics until Jnana’s sale to Otsuka Pharmaceutical. Caroline led the team responsible for corporate and business development, alliance management, legal contracts, new product planning, and communications. Before Jnana, she spent over a decade at Alnylam Pharmaceuticals; in her final role there, she served as VP of Business Development. During this time, she led the formation of a variety of high-impact partnerships including a 5-year collaboration with Regeneron Pharmaceuticals to discover and develop new RNA interference (RNAi) therapeutics. Prior to Alnylam, Caroline served in business development at Amicus Therapeutics and started her career as a strategy consultant at Bain & Company. Caroline received her MBA from the MIT Sloan School of Management and a Bachelor of Economics from Duke University.
“I believe that the most meaningful growth happens in organizations where scientific excellence and business strategy work seamlessly together while focusing on the patient as the North-Star. Sionna embodies this approach, which is why I’m thrilled to join the company,” said Caroline. "I look forward to helping Sionna execute on its mission, striving toward enhanced options for CF patients.”
About Sionna Therapeutics
Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Sionna’s goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide binding domain 1 (NBD1), which Sionna believes is central to potentially unlocking dramatic improvements in clinical outcomes and quality of life for people with CF. Leveraging more than a decade of the co-founders’ research on NBD1, Sionna is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in NBD1. Sionna is also developing a portfolio of complementary CFTR modulators that are designed to work synergistically with its NBD1 stabilizers to improve CFTR function. For information about Sionna, visit www.sionnatx.com.
Sionna intends to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Sionna’s Investor Relations website, in addition to following Sionna’s press releases, SEC filings, public conference calls, presentations, and webcasts.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about Sionna’s beliefs and expectations regarding its goal of transforming the treatment paradigm for CF and providing innovative and transformative treatment options to CF patients. In some cases, the forward-looking statements can be identified by terms such as “may,” “will,” “should,” “would,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties inherent in the development of product candidates, including uncertainties concerning the initiation, timing, progress, and results of Sionna’s ongoing, planned and future clinical trials and studies; the company’s ability to replicate positive results from earlier preclinical studies or clinical trials in current or future clinical trials; Sionna’s ability to demonstrate that its NBD1 stabilizers, complementary CFTR modulators, and any potential future product candidates are safe and effective for their proposed indications; regulatory developments in the United States and foreign countries; and general economic, industry and market conditions. These risks and uncertainties are described in the section entitled “Risk Factors” in Sionna’s most recent Quarterly Report on Form 10-Q as well as any subsequent filings with the Securities and Exchange Commission. The events and circumstances reflected in the forward-looking statements may not be achieved or occur. In addition, any forward-looking statements represent Sionna’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Sionna explicitly disclaims any obligation to update any forward-looking statements except as required by law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Media Contact
Adam Daley
CG Life
212.253.8881
adaley@cglife.com
Investor Contact
Juliet Labadorf
ir@sionnatx.com
FAQ
Who is Caroline Stark Beer and what is her new role at Sionna Therapeutics (SION)?
What is Sionna Therapeutics (SION) developing?
What is Caroline Stark Beer's previous experience before joining Sionna (SION)?
What notable partnerships did Caroline Stark Beer establish in her previous roles?
